FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2050503506> ?p ?o ?g. }

• W2050503506 endingPage "378" @default.
• W2050503506 startingPage "378" @default.
• W2050503506 abstract "Case Studies1 September 1963Ochronosis from Quinacrine (Atabrine)GEORGE D. LUDWIG, M.D., JAMES F. TOOLE, M.D., JOHN C. WOOD, M.D.GEORGE D. LUDWIG, M.D.Search for more papers by this author, JAMES F. TOOLE, M.D.Search for more papers by this author, JOHN C. WOOD, M.D.Search for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-59-3-378 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptOchronosis is usually associated with the rare hereditary metabolic disease, alcaptonuria, in which there is a defect in the hepatic enzyme, homogentisic acid oxidase, and consequently an accumulation in the blood and spill-over in the urine of homogentisic acid (1, 2). The term ochronosis was coined by Virchow (3) in 1866, to describe the grossly blue-black but microscopically yellow-brown (ochre) pigmentation of cartilage and other connective tissue found at necropsy in a 57-year-old man. In 1902, Albrecht (4) first suggested that alcaptonuria might cause ochronosis, and in 1904, Sir William Osler (5) made the first clinical diagnosis of alcaptonuric ochronosis...References1. BUNIMMCGUIREHILBISHLASTERLADUSEEGMILLER JJJSTFLBNJE: Alkaptonuria: Clinical Staff Conference at the National Institutes of Health. Ann. Intern. Med. 47: 1210, 1957. LinkGoogle Scholar2. LADUZANNONLASTERSEEGMILLER BNVLJE: The nature of the defect in tyrosine metabolism in alcaptonuria. J. Biol. Chem. 230: 251, 1958. CrossrefMedlineGoogle Scholar3. VIRCHOW R: Ein Fall von allgemeiner Ochronose der Knorpel und Knorpelahnlichen theile. Virchow Arch. path. Anat. 37: 212, 1866. CrossrefGoogle Scholar4. ALBRECHT H: Ueber ochronose. Z. Heil. path. Anat. 23: 366, 1902. Google Scholar5. OSLER W: Ochronosis: the pigmentation of cartilage sclerotics and skin in alkaptonuria. Lancet 1: 10, 1904. CrossrefGoogle Scholar6. POPE FM: A case of ochronosis. With a note on the relationship of alkaptonuria to ochronosis by A. E. Garrod. Lancet 1: 24, 1906. CrossrefGoogle Scholar7. PICK L: Ueber die Ochronose. Ber. klin. Wschr. 43: 478, 509, 556, 591, 1906. Google Scholar8. BEDDARD AP: Ochronosis associated with carboluria. Quart. J. Med. 3: 329, 1910. Google Scholar9. SUGARWADDELL HSWW: Ochronosis-like pigmentation associated with the use of atabrine. Illinois Med. J. 89: 234, 1946. Google Scholar10. LUTTERLOHSHALLENBERGER CHPL: Unusual pigmentation developing after prolonged suppressive therapy with quinacrine hydrochloride. Arch. Derm. Syph. (Chic.) 53: 349, 1946. CrossrefMedlineGoogle Scholar11. GOLDSCHMIDT RB: Experimentelle Mutation und das Problem der sogenannten Parallel-induktion. Biol. Zbl. 49: 437, 1929. Google Scholar12. GOLDSCHMIDT RB: Theoretical Genetics, University of California Press, Los Angeles, 1955, p. 256. CrossrefGoogle Scholar13. TROPPWEISE CW: Untersuchungen uber die Ausscheidung von Atebrin durch Harn und Fazes. Arch. exp. Path. Pharm. 170: 339, 1933. CrossrefGoogle Scholar14. SJOERDSMADAVIDSONUNDENFRIENDMITOMA AJDSC: Increased excretion of hydroxyproline in Marfan's syndrome. Lancet 2: 994, 1958. CrossrefMedlineGoogle Scholar15. PROCKOPSJOERDSMA DJA: Significance of urinary hydroxyproline in man. J. Clin. Invest. 40: 843, 1961. CrossrefMedlineGoogle Scholar16. GREILING H: Beitrag zur Entstehung der Ochronose bei Alkaptonurie. Klin. Wschr. 35: 889, 1957. CrossrefMedlineGoogle Scholar17. GOODMANGILMAN LSA: The Pharmacological Basis of Therapeutics; A Textbook of Pharmacology, 2nd ed., The Macmillian Company, New York, 1955, p. 1169. Google Scholar18. STANBURYWYNGAARDENFREDRICKSON JBJBDS, editors: The Metabolic Basis of Inherited Disease, McGraw-Hill Book Company, Inc., New York, p. 400. Google Scholar19. MERWINWINKELMAN CFRK: Antimalarial drugs in the therapy of lupus erythematosus. Proc. Mayo Clin. 37: 253, 1962. MedlineGoogle Scholar20. PAGE F: Treatment of lupus erythematosus with mepacrine. Lancet 2: 755, 1951. CrossrefMedlineGoogle Scholar21. O'LEARYBRUNSTINGKIERLAND PALARR: Quinacrine (Atabrine) hydrochloride in treatment of discoid lupus erythematosus. Arch. Derm. Syph. (Chic.) 67: 633, 1953. CrossrefMedlineGoogle Scholar22. KIERLANDBRUNSTINGO'LEARY RRLAPA: Quinacrine hydrochloride (Atabrine) in the treatment of lupus erythematosus. Arch. Derm. Syph. (Chic.) 68: 651, 1953. CrossrefMedlineGoogle Scholar23. SÖDERSTRÖM N: Two cases of sarcoidosis treated with mepacrine. Lancet 2: 947, 1960. CrossrefGoogle Scholar24. KLAUDER JV: Sarcoid of the eyelids, conjunctiva and uveal tract treated with quinacrine hydrochloride (Atabrine). Arch. Derm. Syph. (Chic.) 68: 474, 1953. MedlineGoogle Scholar25. SAMITZSATANOVEKIRSHBAUM MHAB: Sarcoidosis treated with quinacrine hydrochloride (Atabrine dihydrochloride). Ibid., 472. Google Scholar26. SIBLEYTUCKERRANDT WAHJCT: Quinacrine in the treatment of refractory petit-mal epilepsy. New Eng. J. Med. 267: 332, 1962. CrossrefMedlineGoogle Scholar27. MILLICHAP G: Discussion, Meeting of American Academy of Neurology, April, 1962. Google Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: Philadelphia, PennsylvaniaFrom the Department of Medicine and Neurology, University of Pennsylvania, Philadelphia, Pennsylvania.Requests for reprints should be addressed to George D. Ludwig, M.D., Hospital of the University of Pennsylvania, Department of Medicine and Neurology, 3400 Spruce St., Philadelphia 4, Pennsylvania. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byMetabolic Disorders and the SkinAlkaptonuric ochronosis: a clinical study from Ardabil, IranWidespread Use of Toxic Skin Lightening Compounds: Medical and Psychosocial AspectsHydroquinone-induced exogenous ochronosis: a report of four cases and usefulness of dermoscopyStoffwechselkrankheitenRegional Dermatoses in the African.Exogenous ochronosis resulting from quinine injectionsGelenkeMetabolic Diseases and the SkinLocalized exogenous ochronosisIdiopathic pigmentation of the hands. Professional exogenous ochronosis? A new entity?The skin in genetically-controlled metabolic disorders.Recognizing and Managing Drug EruptionsMedical genetics 1963 1 September 1963Volume 59, Issue 3Page: 378-384KeywordsArthritisCartilageConnective tissueEnzymesExcretionIngestionLesionsMetabolic disordersNeurologyUrine Issue Published: 1 September 1963 PDF downloadLoading ..." @default.
• W2050503506 created "2016-06-24" @default.
• W2050503506 creator A5057357404 @default.
• W2050503506 date "1963-09-01" @default.
• W2050503506 modified "2023-10-13" @default.
• W2050503506 title "Ochronosis from Quinacrine (Atabrine)" @default.
• W2050503506 cites W1563615273 @default.
• W2050503506 cites W1583691473 @default.
• W2050503506 cites W1973660901 @default.
• W2050503506 cites W1998359190 @default.
• W2050503506 cites W2028060676 @default.
• W2050503506 cites W2044326124 @default.
• W2050503506 cites W2044736393 @default.
• W2050503506 cites W2051215406 @default.
• W2050503506 cites W2071686966 @default.
• W2050503506 cites W2074451842 @default.
• W2050503506 cites W2097547032 @default.
• W2050503506 cites W2115133188 @default.
• W2050503506 cites W2337836875 @default.
• W2050503506 cites W2338870786 @default.
• W2050503506 cites W2460485801 @default.
• W2050503506 doi "https://doi.org/10.7326/0003-4819-59-3-378" @default.
• W2050503506 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/14065956" @default.
• W2050503506 hasPublicationYear "1963" @default.
• W2050503506 type Work @default.
• W2050503506 sameAs 2050503506 @default.
• W2050503506 citedByCount "17" @default.
• W2050503506 countsByYear W20505035062014 @default.
• W2050503506 countsByYear W20505035062019 @default.
• W2050503506 crossrefType "journal-article" @default.
• W2050503506 hasAuthorship W2050503506A5057357404 @default.
• W2050503506 hasConcept C142724271 @default.
• W2050503506 hasConcept C16005928 @default.
• W2050503506 hasConcept C185592680 @default.
• W2050503506 hasConcept C2776255415 @default.
• W2050503506 hasConcept C2776743390 @default.
• W2050503506 hasConcept C2777169657 @default.
• W2050503506 hasConcept C55493867 @default.
• W2050503506 hasConcept C71924100 @default.
• W2050503506 hasConceptScore W2050503506C142724271 @default.
• W2050503506 hasConceptScore W2050503506C16005928 @default.
• W2050503506 hasConceptScore W2050503506C185592680 @default.
• W2050503506 hasConceptScore W2050503506C2776255415 @default.
• W2050503506 hasConceptScore W2050503506C2776743390 @default.
• W2050503506 hasConceptScore W2050503506C2777169657 @default.
• W2050503506 hasConceptScore W2050503506C55493867 @default.
• W2050503506 hasConceptScore W2050503506C71924100 @default.
• W2050503506 hasIssue "3" @default.
• W2050503506 hasLocation W20505035061 @default.
• W2050503506 hasLocation W20505035062 @default.
• W2050503506 hasOpenAccess W2050503506 @default.
• W2050503506 hasPrimaryLocation W20505035061 @default.
• W2050503506 hasRelatedWork W2034705268 @default.
• W2050503506 hasRelatedWork W2118509080 @default.
• W2050503506 hasRelatedWork W2133768386 @default.
• W2050503506 hasRelatedWork W2398336517 @default.
• W2050503506 hasRelatedWork W2619751108 @default.
• W2050503506 hasRelatedWork W2959149350 @default.
• W2050503506 hasRelatedWork W4236775904 @default.
• W2050503506 hasRelatedWork W4289535781 @default.
• W2050503506 hasRelatedWork W4292289241 @default.
• W2050503506 hasRelatedWork W9014468 @default.
• W2050503506 hasVolume "59" @default.
• W2050503506 isParatext "false" @default.
• W2050503506 isRetracted "false" @default.
• W2050503506 magId "2050503506" @default.
• W2050503506 workType "article" @default.